Studies have revealed that valerate and butyrate significantly enhance the anti-tumour activity of cytotoxic T lymphocytes (CTLs) and chimeric antigen receptor (CAR) T cells by increasing the production of effector cytokines (CD25, IFN-γ and TNF-α) in CD8+ T cells. This evidence concerns the gene CD8A and neoplasm.